Luis Almeida
Overview
Explore the profile of Luis Almeida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
138
Citations
2099
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henriques S, Leblanc A, Simoes S, Fonseca M, Pimentel F, Almeida L, et al.
Pharmaceutics
. 2025 Jan;
16(12.
PMID: 39771558
When companies are uncertain about the potential of a new formulation to be bioequivalent to a Reference product, it is common practice to carry out downsized pilot studies as a...
2.
Almeida L, Bellver-Arnau J, Privat Y, Rebelo C
J Math Biol
. 2024 Nov;
89(6):63.
PMID: 39532731
This paper is devoted to the study of optimal release strategies to control vector-borne diseases, such as dengue, Zika, chikungunya and malaria. Two techniques are considered: the sterile insect one...
3.
Heieis G, Patente T, Almeida L, Vrieling F, Tak T, Perona-Wright G, et al.
Nat Commun
. 2024 Jul;
15(1):6452.
PMID: 39085251
No abstract available.
4.
Fonseca M, Ribeiro C, Castilla-Fernandez G, Gama H, Magalhaes L, Henriques S, et al.
Br J Clin Pharmacol
. 2024 Jul;
90(11):2781-2792.
PMID: 38970469
Aims: Dopamine beta-hydroxylase (DβH) inhibitors, like zamicastat, hold promise for treating pulmonary arterial hypertension. This study aimed to validate the mechanism of action of zamicastat by studying its effect on...
5.
Fonseca M, Guimaraes A, Gama H, Magalhaes L, Henriques S, Silva N, et al.
J Clin Pharmacol
. 2024 Jun;
64(11):1361-1372.
PMID: 38924604
This study intended to evaluate the interactions between zamicastat and epoprostenol in healthy human subjects. This was a single-center, open-label, two-period study. In period 1, epoprostenol 8 ng/kg/min was administered...
6.
Almeida L, van Roey R, Patente T, Otto F, Veldhuizen T, Ghorasaini M, et al.
Front Immunol
. 2024 May;
15:1372927.
PMID: 38742105
The parasitic helminth is a potent inducer of type 2 immune responses by stimulating dendritic cells (DCs) to prime T helper 2 (Th2) responses. We previously found that soluble egg...
7.
Leschiera E, Al-Hity G, Flint M, Venkataraman C, Lorenzi T, Almeida L, et al.
Phys Biol
. 2024 Jan;
21(2).
PMID: 38266283
In recentexperiments on co-culture between breast tumour spheroids and activated immune cells, it was observed that the introduction of the stress hormone cortisol resulted in a decreased immune cell infiltration...
8.
Almeida L, Denis J, Ferrand N, Lorenzi T, Prunet A, Sabbah M, et al.
J R Soc Interface
. 2024 Jan;
21(210):20230587.
PMID: 38196375
Glucose is a primary energy source for cancer cells. Several lines of evidence support the idea that monocarboxylate transporters, such as MCT1, elicit metabolic reprogramming of cancer cells in glucose-poor...
9.
Almeida L, Dhillon-LaBrooy A, Sparwasser T
Trends Endocrinol Metab
. 2023 Dec;
35(3):235-248.
PMID: 38040578
The function and phenotype of macrophages are intimately linked with pathogen detection. On sensing pathogen-derived signals and molecules, macrophages undergo a carefully orchestrated process of polarization to acquire pathogen-clearing properties....
10.
Henriques S, Paixao P, Almeida L, Silva N
Pharmaceutics
. 2023 Oct;
15(10).
PMID: 37896259
Pilot bioavailability/bioequivalence (BA/BE) studies are downsized trials that can be conducted prior to the definitive pivotal trial. In these trials, 12 to 18 subjects are usually enrolled, although, in principle,...